Factors linked to complete responses to immunotherapy in metastatic melanoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single‑center retrospective review of patients with unresectable stage III or stage IV melanoma treated with curative‑intent anti‑PD‑1 and/or anti‑CTLA‑4 immunotherapy at the Strasbourg University Hospitals between January 1, 2013 and December 31, 2021. Investigators will use medical records from the Dermatology Department to identify clinical, pathological, and treatment features associated with complete and sustained responses. Patients with primary choroidal melanoma, those receiving adjuvant immunotherapy, those treated outside the dermatology department, or with less than three months of follow‑up are excluded. The goal is to find additional predictive factors not yet reported in the literature while building on previously recognized markers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years;
* Unresectable stage III or stage IV melanoma according to the AJCC classification - 8th edition;
* Curative immunotherapy treatment (anti-PD-1 and/or anti-CTLA-4);
* Treatment and follow-up at the Dermatology Department of the Strasbourg University Hospitals;
* Immunotherapy initiated between January 1, 2013, and December 31, 2021.

Exclusion Criteria:

* Primary choroidal melanoma;
* Adjuvant-intent immunotherapy;
* Less than 3 months of follow-up after the start of immunotherapy;
* Change of treatment before the first reassessment;
* Treatment and follow-up at a department other than the Dermatology Department of the Strasbourg University Hospitals.

Where it's running

• Service de dermatologie - Réanimation - CHU de Strasbourg - France
  Strasbourg, France Recruiting

Study contacts

• Study coordinator: Cédric LENORMAND, MD
• Email: cedric.lenormand@chru-strasbourg.fr
• Phone: 33 3 88 11 66 27

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NeoAdjuvant PD-1–Based Therapy in Resectable Advanced Melanoma (NASA)

  In people with resectable stage IIIB–IV melanoma, this study tests whether two infusions of pembrolizumab or a combination of ipilimumab plus nivolumab given before surgery can keep people alive at 2 years without needing additional adjuvant therapy.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07740941

• Urinary microbiome as a biomarker for melanoma diagnosis and treatment response

  This study tests whether bacteria in urine can help diagnose melanoma and predict how well patients will respond to systemic therapy.

  Recruiting Medical University of Graz · Gratwein, Styria · NCT07635732

• Using Cyclophosphamide and Pembrolizumab for advanced melanoma treatment

  This study is testing if a combination of Cyclophosphamide and Pembrolizumab can help people with advanced melanoma who haven't responded to other treatments feel better and improve their health.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06771544

• Long-term follow-up for patients treated with Miltenyi CAR T therapies

  This study looks at how well Miltenyi CAR T cell therapies work and their long-term safety for patients, especially kids, who have already been treated.

  Recruiting at 2 sites Miltenyi Biomedicine GmbH · Berlin and 6 other locations · NCT06508775

• Treatment of advanced solid tumors with VET3-TGI immunotherapy

  This study is testing a new cancer treatment called VET3-TGI to see if it can safely target and kill cancer cells in patients with advanced solid tumors, either by injecting it directly into the tumors or giving it through an IV.

  Recruiting at 7 sites Phase 1 KaliVir Immunotherapeutics · Los Angeles, California and 6 other locations · NCT06444815

• Testing GIM-531 for advanced solid tumors

  This study is testing a new oral medication called GIM-531 to see if it can help people with advanced solid tumors, especially those with melanoma that hasn't improved after other treatments.

  Recruiting at 11 sites Phase 1/2 Georgiamune Inc · Scottsdale, Arizona and 10 other locations · NCT06425926

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.